These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 20334824)

  • 21. Does the prophylactic use of N-acetylcysteine prevent contrast nephropathy in patients with renal insufficiency?
    Ma IW; Hladunewich M
    CMAJ; 2004 Apr; 170(8):1231. PubMed ID: 15078844
    [No Abstract]   [Full Text] [Related]  

  • 22. Sodium bicarbonate versus sodium chloride and oral N-acetylcysteine for the prevention of contrast-induced nephropathy in advanced chronic kidney disease.
    Shavit L; Korenfeld R; Lifschitz M; Butnaru A; Slotki I
    J Interv Cardiol; 2009 Dec; 22(6):556-63. PubMed ID: 19732281
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acetylcysteine and non-ionic isosmolar contrast-induced nephropathy--a randomized controlled study.
    Ferrario F; Barone MT; Landoni G; Genderini A; Heidemperger M; Trezzi M; Piccaluga E; Danna P; Scorza D
    Nephrol Dial Transplant; 2009 Oct; 24(10):3103-7. PubMed ID: 19549691
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Renal effects of N-acetylcysteine in patients at risk for contrast nephropathy: decrease in oxidant stress-mediated renal tubular injury.
    Drager LF; Andrade L; Barros de Toledo JF; Laurindo FR; Machado César LA; Seguro AC
    Nephrol Dial Transplant; 2004 Jul; 19(7):1803-7. PubMed ID: 15128882
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A review of contemporary prevention strategies for radiocontrast nephropathy: a focus on fenoldopam and N-acetylcysteine.
    Lepor NE
    Rev Cardiovasc Med; 2003; 4 Suppl 1():S15-20. PubMed ID: 12556733
    [TBL] [Abstract][Full Text] [Related]  

  • 26. N-acetylcysteine and contrast-induced nephropathy in primary angioplasty.
    Marenzi G; Assanelli E; Marana I; Lauri G; Campodonico J; Grazi M; De Metrio M; Galli S; Fabbiocchi F; Montorsi P; Veglia F; Bartorelli AL
    N Engl J Med; 2006 Jun; 354(26):2773-82. PubMed ID: 16807414
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical practice. Preventing nephropathy induced by contrast medium.
    Barrett BJ; Parfrey PS
    N Engl J Med; 2006 Jan; 354(4):379-86. PubMed ID: 16436769
    [No Abstract]   [Full Text] [Related]  

  • 28. N-acetylcysteine for prevention of radiographic contrast material-induced nephropathy: is the intravenous route best?
    Shalansky SJ; Vu T; Pate GE; Levin A; Humphries KH; Webb JG
    Pharmacotherapy; 2005 Aug; 25(8):1095-103. PubMed ID: 16207100
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Re: Contrast media-induced nephrotoxicity: identification of patients at risk and algorithms for prevention.
    Funaki B
    J Vasc Interv Radiol; 2001 Jul; 12(7):894. PubMed ID: 11435549
    [No Abstract]   [Full Text] [Related]  

  • 30. Contrast-induced nephropathy remains a serious complication of PCI.
    Mehran R
    J Interv Cardiol; 2007 Jun; 20(3):236-40. PubMed ID: 17524117
    [No Abstract]   [Full Text] [Related]  

  • 31. N-acetylcysteine and contrast-induced nephropathy.
    Aguiar-Souto P; Valero-González S; Domínguez JF
    N Engl J Med; 2006 Oct; 355(14):1497-8; author reply 1499-500. PubMed ID: 17021328
    [No Abstract]   [Full Text] [Related]  

  • 32. Acetylcysteine In Diabetes (AID): a randomized study of acetylcysteine for the prevention of contrast nephropathy in diabetics.
    Coyle LC; Rodriguez A; Jeschke RE; Simon-Lee A; Abbott KC; Taylor AJ
    Am Heart J; 2006 May; 151(5):1032.e9-12. PubMed ID: 16644332
    [TBL] [Abstract][Full Text] [Related]  

  • 33. N-acetylcysteine for prevention of radiocontrast induced nephrotoxicity: the importance of dose and route of administration.
    Shalansky SJ; Pate GE; Levin A; Webb JG
    Heart; 2005 Aug; 91(8):997-9. PubMed ID: 16020580
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevention of contrast-induced nephropathy: an overview.
    Ellis JH; Cohan RH
    Radiol Clin North Am; 2009 Sep; 47(5):801-11, v. PubMed ID: 19744595
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of N-acetylcysteine and fenoldopam for preventing contrast-induced nephropathy (CAFCIN).
    Ng TM; Shurmur SW; Silver M; Nissen LR; O'Leary EL; Rigmaiden RS; Cieciorka M; Porter LL; Ineck BA; Kline ME; Puumala SE
    Int J Cardiol; 2006 May; 109(3):322-8. PubMed ID: 16039733
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [ Use of N-acetylcysteine for the prevention of contrast-induced nephropathy in rats].
    Inci MF; Salk I; Solak O; Vurdem UE; Inci R
    Actas Urol Esp; 2012 Apr; 36(4):210-5. PubMed ID: 22548227
    [No Abstract]   [Full Text] [Related]  

  • 37. N-acetylcysteine somewhere between Scylla and Charybdis.
    Sochman J
    J Am Coll Cardiol; 2010 Sep; 56(13):1067; author reply 1067-8. PubMed ID: 20846610
    [No Abstract]   [Full Text] [Related]  

  • 38. Contrast associated nephropathy in the elderly.
    Carrillo-Alvira F; Rivera-Bermúdez CG; Jiménez-Velázquez IZ; Ramos-Romey C; González-Concepción JJ
    Bol Asoc Med P R; 2008; 100(3):25-7. PubMed ID: 19227712
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Is acetylcysteine effective in preventing contrast-related nephropathy? A meta-analysis.
    Nallamothu BK; Shojania KG; Saint S; Hofer TP; Humes HD; Moscucci M; Bates ER
    Am J Med; 2004 Dec; 117(12):938-47. PubMed ID: 15629733
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevention of contrast-induced nephropathy in high-risk patients with hemofiltration.
    Coca SG; Perazella MA
    Am J Med; 2007 Aug; 120(8):e9; author reply e11. PubMed ID: 17679116
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.